NASDAQ · Biotechnology

Chimerix, Inc. (CMRX) Stock

$8.54 +0.00% NASDAQ: CMRX Healthcare

Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions.

Valuation

MetricValue
Price$8.54
Market Cap$801.08M
P/E Ratio-8.63
P/B Ratio6.30
P/S Ratio3778.70
EPS (TTM)$-0.99
52-Week High$8.55
52-Week Low$0.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-56.17%
ROA-60.54%
ROCE-79.06%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity0.00
Current Ratio5.70

Annual Financials (USD)

Metric20202021202220232024
Revenue$5.0M$2.0M$34.0M$0$0
Operating Profit$-45.0M$-173.0M$-60.0M$-93.0M$-97.0M
Net Profit$-42.0M$-256.0M$172.0M$-82.0M$-88.0M
EPS$-0.68$-3.01$1.94$-0.93$-0.99
Op Margin-828.7%-8762.0%-178.5%-28723.8%-45550.5%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$85.0M$101.0M$279.0M$213.0M$146.0M
Total Liabilities$11.0M$32.0M$22.0M$20.0M$24.0M
Cash$47.0M$15.0M$26.0M$28.0M$31.0M
Borrowings$3.0M$16.0M$2.0M$1.0M$0

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-36.0M$-100.0M$-47.0M$-69.0M$-75.0M
Investing Cash Flow$129.0M$-44.0M$140.0M$71.0M$71.0M
Financing Cash Flow$1.0M$5.0M$0$0$0
Net Cash Flow$30.0M$-32.0M$10.0M$2.0M$3.0M
Free Cash Flow$-36.0M$-100.0M$-47.0M$-69.0M$-75.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.81
EV / EBITDA-7.99
FCF Yield-9.40%
Quick Ratio5.80
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Chimerix, Inc.

Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation. ONC206, an imipridone, is a Phase I candidate for solid tumors, functioning as both a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. Notably, it exhibits superior non-competitive antagonism of DRD2 compared to ONC201. ONC212, another imipridone, acts as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. This compound is being explored for a range of solid tumors and blood cancers, including pancreatic cancer and leukemias. dociparstat sodium (DSTAT) aims to overcome chemotherapy resistance in acute myeloid leukemia (AML) by inhibiting crucial proteins found in leukemic blasts and stem cells. Chimerix has also forged strategic partnerships, including licensing agreements with: The Biomedical Advanced Research and Development Authority (BARDA) for brincidofovir's smallpox treatment development. Cantex Pharmaceuticals, Inc. for the development and commercialization of a glycosaminoglycan compound. SymBio Pharmaceuticals for the development, manufacturing, and commercialization of BCV (brincidofovir) across multiple human indications. Established in 2000, Chimerix, Inc. maintains its headquarters in Durham, North Carolina.

Chimerix, Inc. is headquartered in US.

Chimerix, Inc. (CMRX) stock trades at $8.54 with a market capitalization of $801.08M. The stock is valued at a price-to-earnings (P/E) ratio of -8.63, price-to-book of 6.30, price-to-sales of 3778.70. Over the past 52 weeks the stock has ranged between $0.75 and $8.55, and currently trades at its 52-week high.

On profitability, Chimerix, Inc. generates a return on equity (ROE) of -56.17%, return on capital employed of -79.06%.

Official website: www.chimerix.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides